Background {#Sec1}
==========

The proportion of people who are obese or overweight continues to increase, with obese adults and children currently accounting for 37% and 24% of the population worldwide, respectively \[[@CR1]\]. In 2010, research on the global burden of disease showed that obesity or overweight were responsible for 3.9% of the years of life lost and 3.8% of the disability-adjusted life years and caused a global death toll of 3.4 million \[[@CR2]\]. Body mass index (BMI) is an indicator used to systematically measure obesity and overweight status. BMI has been broadly applied in research relating to obesity and overweight because of its convenience of use. Research has shown that high BMI is a risk factor for hypertension and cardiovascular events (CVEs) \[[@CR3]--[@CR7]\]. Hypertension and risk of CVEs are, respectively, 4.17 and 1.46 times higher among those who are obese, compared with those of normal weight \[[@CR3], [@CR6]\].

Obesity and overweight are not only risk factors for hypertension; they are also related to changes in blood pressure (BP). Faramawi \[[@CR8]\] found that, for every one-unit increase in BMI, short-term blood pressure variability (BPV) increased by 0.25. In addition to short-term BPV, BP also has long-term variability, which is caused by factors including the environment and behaviors \[[@CR9]--[@CR11]\], but existing research on BMI and BPV have mainly focused on the impact of BMI on short-term BPV. To the best of our knowledge, there has been almost no research about the effect of BMI on long-term BPV. The Kailuan study (Registration No.: CHiCTR-TNC1100 1489) examines risk factors and interventions for CVEs based the full population of staff members working for the Kailuan Group. Since 2006, a physical examination has been conducted every 2 years among the observation group. This examination includes measurements of BP, height, and weight, offering an opportunity to study the impact of BMI on long-term BPV.

Methods {#Sec2}
=======

Study participants {#Sec3}
------------------

Following a cross-sectional study design, since 2006--2007 (hereafter "2006"), 11 hospitals affiliated with Kailuan Hospital have conducted physical examinations on their current, dismissed, and retired staff members, collecting body measurements and biochemical indexes. All the staff came from China. They were included in the study subjects if they had met the following criteria: aged 18 years or older; with complete data on height and weight; with no history of CVEs. The same medical staff who conducted the first health examination continued to examine the same group of people at the same sites every 2 years in the same chronological order, making up the second (2008--2009), third (2010--2011), fourth (2012--2013), and fifth (2014--2015) waves of data collection (referred to in this article as "2008," "2010," "2012," and "2014," respectively). The investigation content, anthropometric measurements, and biochemical index tests were identical at each wave. Those who had missed any systolic blood pressure (SBP) test across the five study waves and incidence of CVEs between first and fifth physical examinations were excluded. In accordance with the Helsinki Declaration, this study has been approved by the Ethics Committee of Kailuan General Hospital, and written informed consent was obtained from all individuals in the observation group.

Data collection {#Sec4}
---------------

Details of the epidemiological investigation and anthropometry index have been described elsewhere \[[@CR12]\]. Smoking was operationalized as smoking at least one cigarette per day on average in the last year. Drinking was operationalized as consuming more than 300 ml of liquor (alcohol concentration \> 50% volume per volume) per day for at least 1 year. Physical exercise was defined as exercising more than three times per week, with each time lasting more than 30 min. CVEs included stroke (namely, hemorrhagic stroke or ischemic stroke) and myocardial infarction.Trained medical staff members checked all of the inpatient diagnoses for individuals in the study group at the hospitals in the Kailuan Group and at the hospitals that were municipally listed for medical insurance every year. These staff members also recorded final events. All of these diagnoses were confirmed by professional doctors in line with inpatient records.

For the measurement of BP, subjects were required to refrain from smoking or drinking tea or coffee for 30 min before the measurement and to sit upright for 15 min quietly. The measurement was taken with the subject sitting with his/her bare right upper arm slightly stretched out, with the elbow lying at the same level as the heart. A suitable cuff was selected for the subject's upper arm circumference and was then wound with moderate tension, close to the skin of the upper arm, with the cuff's upper edge approximately 2.5 cm above the chelidon and centered over the brachial artery. The first four physical examinations used an adjusted mercury sphygmomanometer to test the BP of the right brachial artery. The SBP reading used Korotkoff sounds phase one, and the DBP reading used the fifth phase. For the fifth physical examination, an Omron electronic sphygmomanometer (HEM-8102A, Omron Co., Ltd. Daling China) was used to measure the BP of the right brachial artery. During each physical examination, BP was tested three times, with an interval of 1 min between tests, and the average of these three readings was recorded as the final BP of each subject.

To measure height and weight, trained medical staff members use an adjusted scale (model RGZ-120) to measure the subject's height and weight from 7:30 a.m. to 9:00 a.m. For these measurements, the subjects were barefoot, had nothing on their heads, wore light clothing, and stood upright. Height was measured to the nearest 0.1 cm, and weight was measured to the nearest 0.1 kg.

Biochemical measurements {#Sec5}
------------------------

Blood samples taken from the antecubital vein were collected in EDTA tubes from the participants fasting overnight. By centrifugating at 3000 g for 10 min (centrifuge radius of 17 cm) at room temperature, plasma was then isolated. The measurement of supernatant serum was carried out in 4 h. Hexokinase/glucose-6-phosphate dehydrogenase method was adopted to measure fasting blood glucose. Total cholesterol (TC) was measured enzymatically (Mind Bioengineering Co. Ltd., Shanghai, China). All biochemical variables were measured by an automatic biochemical analyzer (Hitachi 747; Hitachi, Tokyo, Japan).

Relevant definitions {#Sec6}
--------------------

### Hypertension and diabetes {#Sec7}

Hypertension was defined as having a history of hypertension, SBP ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, or SBP \< 140 mmHg and/or DBP \< 90 mmHg but taking antihypertensive drugs. Criteria for diabetes was a fasting glucose level of 126 mg/dL (7.0 mmol/L) or greater, or use of medications used to treat hyperglycemia.

### BMI {#Sec8}

BMI was calculated as weight/height^2^ (unit: kg/m^2^).

### Long-term blood pressure variability {#Sec9}

Measures of long-term BPV \[[@CR13]\] include the standard deviation of BP, the coefficient of variation, the variability uncorrelated with mean BP, and the average real variability (ARV). ARV requires that the order of the BP readings be in line with the formula. This measurement can better predict damage to the target organ \[[@CR14]--[@CR16]\]. For this reason, ARV was adopted in the present study to estimate long-term BPV. The average real variability of systolic blood pressure (ARVSBP) was calculated using the following formula: ARVSBP = (\|sbp2 − sbp1\| + \|sbp3 − sbp2\| + \|sbp4 − sbp3\| + \|sbp5 − sbp4\|)/4, where sbp1, sbp2, sbp3, sbp4, and sbp5 represent the subject's SBP at the first through the fifth physical examinations.

Statistical methods {#Sec10}
-------------------

All of the information from the physical examinations was recorded by unifying trained professional staff members and gathered by Kailuan General Hospital. SPSS 13.0 (SPSS, Chicago, IL, USA) was used for the data analysis. Averages ± standard deviations (x̅ ± s) were calculated for continuous variables. Single-factor analysis of variance was used for group comparisons, comparing averages using the least significant difference test in cases of variance homogeneity or Dunnett's T3 test in cases of variance non-homogeneity For categorical variables, n (%) was reported, and the χ^2^ test was used for group comparisons. Stepwise multiple linear regression models were used to analyze the impact of BMI on ARVSBP, and logistic regression models were used to estimate the risk of an increase in ARVSBP associated with BMI. For the latter analysis, the subjects were divided into two groups according to ARVSBP (less than vs. equal to or greater than the average ARVSBP \[12.64\]). Differences were considered statistically significant if *P* \< 0.05 (two-sided test).

Including patients with hypertension and those taking antihypertensive drugs, and using different methods of measuring BP may affect our assessment of long-term BPV. Therefore, patients with hypertension, those taking antihypertensive drugs, and the fifth physical examination (which used a electronic sphygmomanometer to measure BP) were sequentially excluded in a sensitivity analysis, where we calculated the effect of BMI using partial regression coefficients, odds ratios (OR), and 95% confidence intervals (95% CI) of ARVSBP. Here, differences were considered statistically significant if *P* \< 0.05 (two-side test).

Results {#Sec11}
=======

Study subjects' general information {#Sec12}
-----------------------------------

A total of 101,510 subjects were enrolled in the physical examination in 2006. Excluding the 3330 cases with previous CVEs and the 1487 cases with incomplete information or missing weight or height at the first physical examination reduced the sample to 37,432 cases who took part in physical examinations in all of the study years (2008, 2010, 2012, and 2014). We then excluded the 3068 cases with missing data on SBP at any physical examination and the 1882 cases of new occurrence of CVEs during the study period. Finally, the remaining 32,482 cases (including 24,502 men \[75.4%\]; overall average age = 46.6 ± 11.3 years) were included in the statistical analysis (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Inclusion/exclusion flowchart for study subjects

According to the criteria for defining obesity in China, the subjects were divided into four groups by BMI \[[@CR17]\]: underweight (BMI \< 18.5 kg/m^2^), normal weight (18.5 ≤ BMI \< 24.0 kg/m^2^), overweight (24.0 ≤ BMI \< 28.0 kg/m^2^), and obese (BMI ≥ 28.0 kg/m^2^). An increase in BMI was associated with higher values for age, SBP at all five physical examinations, heart rate (HR), TC, and salt intake, and being male, drinking alcohol, engaging in physical exercise, smoking, having diabetes mellitus (DM), having hypertension, and taking antihypertensive drugs (*P* \< 0.05). As BMI increases, the mean value of ARVSBP gradually increases (*P* \< 0.0001). After the underweight group was combined with the normal-weight group (because there were only 490 underweight cases), the mean ARVSBP and the proportion of ARVSBP above or equal to the average increased with an increase in BMI (*P* \< 0.0001) (see Table [1](#Tab1){ref-type="table"}).Table 1Subjects' basic characteristics by BMI groupVariableBMI \< 18.5\
(*N* = 490)\[18.5,24)\
(*N* = 12,369)\[24,28)\
(*N* = 13,622)\> = 28\
(6001)Total\
(*N* = 32,482)*P*Age(year)43.0 ± 14.445.8 ± 11.747.6 ± 10.946.4 ± 11.1246.6 ± 11.3\< 0.0001HR(beat/min)74.4 ± 12.473.3 ± 10.073.1 ± 9.4773.9 ± 9.6973.4 ± 9.78\< 0.0001TC(mmol/L)4.66 ± 0.994.79 ± 1.084.94 ± 1.194.98 ± 1.154.89 ± 1.14\< 0.0001SBP1114 ± 15.7121 ± 17.5129 ± 18.5134 ± 19.2127 ± 18.9\< 0.0001SBP2116 ± 16.9123 ± 17.8130 ± 18.1135 ± 18.6128 ± 18.7\< 0.0001SBP3118 ± 17.6124 ± 17.3131 ± 17.7135 ± 17.9129 ± 18.1\< 0.0001SBP4118 ± 17.7125 ± 17.8131 ± 17.9135 ± 17.7129 ± 18.3\< 0.0001SBP5124 ± 18.0131 ± 19.3138 ± 19.3141 ± 18.9136 ± 19.7\< 0.0001Male,n(%)295 (60.2)8705 (70.4)10,768 (79.0)4734 (78.9)24,502 (75.4)\< 0.0001Drinking alcohol, n(%)64 (13.1)2103 (17.0)2475 (18.2)915 (15.2)5557 (17.1)\< 0.0001physical exercise, n(%)43 (8.8)1556 (12.6)1838 (13.5)791 (13.2)4228 (13.0)0.005Salt intake, n(%)44 (9.0)1125 (9.1)1478 (10.9)740 (12.3)3387 (10.4)\< 0.0001Smoking, n(%)160 (32.7)4245 (34.3)4801 (35.2)1999 (33.3)11,205 (34.5)0.046Dm, n(%)20 (4.1)516 (4.2)1043 (7.7)616 (10.3)2195 (6.8)\< 0.0001Hypertension, n(%)55 (11.2)2949 (23.8)5489 (40.3)3205 (53.4)11,698 (36.0)\< 0.0001antihypertensive drugs, n(%)3 (0.6)471 (3.8)1149 (8.4)749 (12.5)2372 (7.3)\< 0.0001BPV11.8 ± 5.8212.2 ± 6.3112.8 ± 6.5913.2 ± 6.8512.64 ± 6.53\< 0.0001≥mean BPV194 (39.6)4903 (39.6)5859 (44.0)2782 (46.4)13,868 (42.7)\< 0.0001BPV^a^--12.00 ± 6.3012.8 ± 6.5913.2 ± 6.8512.6 ± 6.53\< 0.0001≥mean BPV^a^--5097 (39.6)5859 (44.0)2782 (46.4)13,868 (42.7)\< 0.0001^a^BPV and BPV ≥ average after merging the underweight (BMI \< 18.5 kg/m^2^) and normal-weight (BMI \< 24.0 kg/m^2^) groups. *BMI* Body mass index, *HR* Heart rate, *TC* Total Cholesterol, sbp1, sbp2, sbp3, sbp4 and sbp5 Systolic blood pressure of the first to the fifth physical examinations, *DM* Diabetes Mellitus, *BPV* Blood pressure variability

The excluded subjects (*n* = 69,028) were older; had higher SBP, HR, and TC; were more likely to be men, to engage in physical exercise, to take antihypertensive drugs, to have hypertension, and to have DM; and were less likely to smoke, compared with the included subjects (*P* \< 0.05). The differences in BMI, salt intake, and drinking alcohol were not statistically significant (see Table [2](#Tab2){ref-type="table"}).Table 2Basics characteristics of included and excluded subjects in 2006GruopIncluding people\
(*N* = 32,482)Excluding people\
(*N* = 69,028)Total\
(*N* = 101,510)*P value*Male, n(%)24,502 (75.4)56,608 (82.0)81,110 (79.9)\< 0.0001Age, year46.6 ± 11.354.4 ± 12.551.9 ± 12.7\< 0.0001SBP1, mm Hg127 ± 18.9133 ± 21.8131 ± 21.1\< 0.0001SBP2, mm Hg128 ± 18.7135 ± 21.8132 ± 21.1\< 0.0001SBP3, mm Hg129 ± 18.1134 ± 20.6131 ± 19.6\< 0.0001SBP4, mm Hg129 ± 18.3135 ± 20.4132 ± 19.6\< 0.0001SBP5, mm Hg136 ± 19.7141 ± 21.3138 ± 20.5\< 0.0001BMI, kg/m^2^25.1 ± 3.4725.0 ± 3.5125.0 ± 3.490.432HR, beat/min73.4 ± 9.7874.0 ± 10.473.8 ± 10.2\< 0.0001TC, mmol/L4.89 ± 1.144.98 ± 1.154.95 ± 1.15\< 0.0001Hypertension, n(%)11,698 (36.0)32,957 (47.7)44,655 (44.0)\< 0.0001Smoke, n(%)11,205 (34.5)22,590 (32.7)33,795 (33.3)\< 0.0001Salt intake, n(%)3387 (10.4)7148 (10.4)10,535 (10.4)0.724Drink, n(%)5557 (17.1)12,038 (17.4)17,595 (17.3)0.198Exercise, n(%)4228 (13.0)11,053 (16.0)15,281 (15.1)\< 0.0001antihypertensive drugs, n(%)2372 (7.3)8942 (13.0)11,314 (11.1)\< 0.0001Dm, n(%)2195 (6.8)7128 (10.3)9323 (9.2)\< 0.0001sbp1, sbp2, sbp3, sbp4 and sbp5: Systolic blood pressure of the first to the fifth physical examinations; *BMI*: Body mass index; *HR*: Heart rate; *TC*: Total Cholesterol; *DM*: Diabetes Mellitus

Stepwise multivariate linear regression analysis of BMI and long-term blood pressure variability {#Sec13}
------------------------------------------------------------------------------------------------

With ARVSBP as the dependent variable and BMI (continuously measured) as the independent variable of interest, the results showed that BMI was positively correlated with ARVSBP. After adjusting for age, gender, drinking alcohol, smoking, engaging in physical exercise, salt intake, TC, HR, DM, and taking antihypertensive drugs, a one-unit increase in BMI was associated with an increase in ARVSBP of 0.077 (*P* \< 0.0001) (see Table [3](#Tab3){ref-type="table"}).Table 3Stepwise multiple linear regression of ARVSBP on continuous BMI^a^ValueableB(95%CI)Beta*SeP*VifAge0.14 (0.14--0.15)0.240.003\< 0.00011.16Gender−0.29(−0.57\--0.14)−0.0190.0860.0011.22HR0.026 (0.018--0.033)0.0380.004\< 0.00011.02TC0.13 (0.065--0.19)0.220.032\< 0.00011.04Drinking0.45 (0.26--0.64)0.0260.10\< 0.00011.25physical exercise−0.35(−0.57\--0.14)−0.0180.110.0011.08Dm0.80 (0.52--1.09)0.0310.15\< 0.00011.04BMI0.077 (0.056--0.097)0.0410.01\< 0.00011.05antihypertensive drugs1.99 (1.71--2.27)0.240.14\< 0.00011.08^a^Adjusting for age, gender, smoking, drinking alcohol, salt intake, physical exercise, TC, HR, DM, and taking antihypertensive drugs. *BMI* Body mass index, *DM* Diabetes Mellitus, *HR* Heart rate, *TC* Total Cholesterol

Logistic regression analysis of the impact of BMI on long-term blood pressure variability {#Sec14}
-----------------------------------------------------------------------------------------

In this part of the analysis, ARVSBP group was the dependent variable, and BMI group was the independent variable of interest, with normal-weight as the reference category. Before adjusting for other confounding factors, the ORs showed that the odds of ARVSBP being above average were 1.32 (95% CI: 1.24--1.40) times higher for the obese group and 1.20 (95% CI 1.14--1.26) times higher for the overweight group, compared with the normal-weight group. After adjusting for age, gender, alcohol consumption, smoking, physical exercise, salt intake, TC, HR, DM, and taking antihypertensive drugs, obesity and overweight were still risk factors for an increase in ARVSBP, with ORs for ARVSBP being above average of 1.23 (95% CI: 1.15--1.32) and 1.10 (95% CI: 1.07--1.19), respectively, both of which were statistically significant (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plot of the logistic analysis of factors affecting the increase of ARVSBP; \**P* for trend = 0.0001; Model 1: unadjusted; Model 2: adjusted for age, gender, smoking, drinking alcohol, salt intake, physical exercise, TC, HR, DM, and taking antihypertensive drugs

Sensitivity analysis {#Sec15}
--------------------

The sensitivity analysis was conducted after separately excluding those with hypertension, those taking antihypertensive drugs, those who were underweight, and measures of BP from the fifth physical examination. Even after adjusting for age, gender, smoking, drinking alcohol, physical exercise, salt intake, TC, HR, DM, and other confounding factors, BMI and ARVSBP were still positively correlated: For every one-unit increase in BMI, ARVSBP increased by 0.027, 0.081, 0.080, or 0.080 in the reduced samples (Table [4](#Tab4){ref-type="table"}).Table 4Stepwise multivariate linear regression analysis of continuous BMI and ARVSBP among sample subgroupspopulationmodelB(CI)BetaSER(R2)*P*Excluding person with hypertensionModel a0.028 (0.005--0.052)0.0160.0120.232 (0.054)0.019Excluding person with treatment for BPModel b0.081 (0.06--0.10)0.0440.0110.261 (0.068)\< 0.0001Excluding the BP in 2014Model c0.080 (0.059--0.10)0.0380.0110.252 (0.063)\< 0.0001Excluding person in low-BMIModel d0.080 (0.059--0.10)0.0410.0110.284 (0.080)\< 0.0001Models a and b: adjusting for age, gender, smoking, drinking alcohol, salt intake, physical exercise, TC, HR, and DM. *DM* Diabetes Mellitus, *HR* Heart rate, *TC* Total CholesterolModels c and d: adjusting for age, gender, smoking, drinking alcohol, salt intake, physical exercise, TC, HR, DM, and taking antihypertensive drugs. *DM* Diabetes Mellitus, *HR* Heart rate, *TC* Total Cholesterol

Discussion {#Sec16}
==========

This study found that BMI and ARVSBP are positively correlated and that people with higher BMI have higher long-term BPV. After adjusting for DM, TC, and other confounding factors, each one-unit increase in BMI is associated with an increase in ARVSBP of 0.077. No previous studies have examined the association of BMI and long-term BPV. However, in a 15-year follow-up study of 681 children with an average age of 14, Li et al. \[[@CR18]\] found that, in an adjusted model, every one-unit increase in BMI was associated with an increase in long-term BPV of 0.029. The results of the present study are consistent with previous studies on the relationship between BMI and short-term BPV. Observing 14,988 people who had undergone health examinations in the United States, Faramawi et al. \[[@CR8]\] found that each one-unit increase in BMI was associated with an increase in short-term BPV of 0.25. In their observation of hypertensive people, Qian et al. \[[@CR19]\] found that the nighttime SBP among obese people was 20.06% higher than that of the normal-weight group.

The inclusion of subjects who were taking antihypertensive drugs and the use of different measurement methods could have had an impact on our findings for ARVSBP. Thus, the present study included a sensitivity analysis that was conducted separately, excluding those with hypertension, those taking antihypertensive drugs, those in the underweight group, and BP measured at the fifth physical examination. The results of this analysis showed that, for every one-unit increase in BMI, ARVSBP increased by 0.028, 0.081, 0.080, or 0.080 in the models excluding the above-mentioned categories, compared with an increase of 0.077 in the original model. This suggests that BMI may have a stronger impact on ARVSBP among hypertensive patients. Studying 6441 health examination cases over a 6-year follow-up, Cao et al. \[[@CR20]\] found that long-term BPV increased in hypertensive patients. In addition, we found that, with the separate exclusion of those taking antihypertensive drugs, those whose BP was measured using a different method, and the underweight group, the effect of BMI on ARVSBP increased. This indicates that antihypertensive drugs weaken the impact of BMI on long-term BPV, there is minimum manual measurement error using an electronic sphygmomanometer, and the lower ARVSBP in the underweight group weakens the effect of BMI on ARVSBP.

This study found that, compared with people of normal weight, the risk of an increase in ARVSBP was 1.23 times higher among obese people and 1.10 times higher among overweight people, after adjusting for diabetes mellitus, antihypertensive drugs, and other confounding factors. This trend was statistically significant. This suggests that the risk of an increase in ARVSBP goes up with a rise in BMI. In addition, there is a dose-dependent relationship between ARVSBP and BMI; that is, the higher the BMI, the higher the ARVSBP. To our knowledge, there has been no previous study of the association between the risk of long-term BPV and obesity.

Because BMI is convenient to measure and widely used in studies related to overweight and obesity, it was selected as the primary indicator of obesity in this study. Previous studies have shown both BMI and waist circumference to be positively correlated with short-term BPV \[[@CR18]\]. BMI and waist circumference are also highly correlated with each other; Freedman et al. \[[@CR21]\] found a strong correlation between BMI and waist circumference (r ≈ 0.9) in a 12-year follow-up of 32,663 adults.

The long-term regulation of BP is affected by a variety of internal and external environmental factors, such as neuroendocrine factors, and vascular wall elasticity. The present study found that high BMI and ARVSBP were positively correlated. The possible reasons for this correlation are as follows: (i) Sleep apnea syndrome may cause long-term BPV to rise by increasing the synthesis of the angiotensin-converting enzyme, and the incidence of sleep apnea is 1.56 times higher among obese people than among people of normal weight. This increased incidence of sleep apnea among obese people may lead to a higher possibility of increases in long-term BPV \[[@CR22], [@CR23]\]. (ii) Vascular wall elasticity is the main regulator of increased BPV. Adipose tissue is an endocrine organ that can release a large number of inflammatory factors, and the long-term damage of inflammatory factors to the endothelial cells leads to higher vascular stiffness, resulting in increased BPV \[[@CR24], [@CR25]\]. (iii) The depressor reflex of the baroreflex receptor is an important mechanism for BPV, which is negatively correlated with the sensitivity of the baroreceptor. BPV may be higher among overweight and obese people because the long-term increase of blood volume decreases the vascular baroreflex sensitivity \[[@CR26]\].

This study is of public health and clinical significance. Obese people have higher BP and long-term BPV. Clinicians can prevent or control hypertension and reduce long-term BPV by advising obese people to lose weight and advising those of normal weight to avoid obesity. For the stabilization of BP among obese hypertensive individuals, clinicians should consider the patient's BP fluctuations in addition to his or her BP when using antihypertensive drugs.

There are some limitations to this study. First, the study population was limited to Kailuan Group staff, and the study failed to consider the factor of race. However, the study population was relatively large, so our findings are still important for the study of obesity and long-term BPV in the Chinese population. Second, BP measurements were collected only on the day of the physical examination; there was no collection of family BP or multiple BP measurements during the year. The relatively long follow-up period (average follow-up of 10 years) of the study makes it important for understanding BPV. Third, in accordance with the strict exclusion and inclusion criteria, many individuals were excluded from the study. As a result, higher values were observed for SBP, hypertension, and age among those who were excluded than among those who were included. These differences may have led to an underestimation of the impact of BMI on ARVSBP. Fourth, because this was a prospective cohort study, the association between BMI changes and BPV could not be explored, and there is relatively weak evidence on this association in previous research. The relationship between changes in BMI and long-term BPV requires further study.

Conclusions {#Sec17}
===========

BMI and ARVSBP are positively correlated, with ARVSBP increasing along with a rise in BMI. BMI is a risk factor for an increase in ARVSBP.
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